Table 1 Clinical outcome and country by treatment in 199 subjects involved in the CYP2D6 PGx analysis
TQ plus CQ (n = 134, total) | PQ plus CQ (n = 31) | CQ plus placebo (n = 34) | ||||
|---|---|---|---|---|---|---|
50 mg (n = 34) | 100 mg (n = 35) | 300 mg (n = 37) | 600 mg (n = 28) | |||
N, subjects (%) per treatment arm | ||||||
Clinical outcome | ||||||
6 month relapse-free (n = 126) | 18 (53) | 17 (49) | 32 (86) | 26 (93) | 23 (74) | 10 (29) |
Relapsed (n = 73) | 16 (47) | 18 (51) | 5 (14) | 2 (7) | 8 (26) | 24 (71) |
Country | ||||||
India (n = 3) | 1 (3) | 1 (3) | 1 (3) | 0 (0) | 0 (0) | 0 (0) |
Peru (n = 114) | 20 (59) | 21 (60) | 19 (51) | 16 (57) | 18 (58) | 20 (59) |
Thailand (n = 82) | 13 (38) | 13 (37) | 17 (46) | 12 (43) | 13 (42) | 14 (41) |